Substance / Medication

Indacaterol

Overview

Active Ingredient
indacaterol
RxNorm CUI
1114326

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

19 trials linked to this intervention

19
Total Trials
0
Recruiting
7
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease.
Cazzola Mario, Rogliani Paola · J Comp Eff Res · 2017
PMID: 28840753Meta-Analysis
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita Nobuyuki, Kaneko Takeshi · Int J Chron Obstruct Pulmon Dis · 2015
PMID: 25960646Meta-AnalysisFull text (PMC)
Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.
Geake James B, Dabscheck Eli J, Wood-Baker Richard et al. · Cochrane Database Syst Rev · 2015
PMID: 25575340Meta-AnalysisFull text (PMC)
Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.
Roskell Neil S, Anzueto Antonio, Hamilton Alan et al. · Int J Chron Obstruct Pulmon Dis · 2014
PMID: 25114521Meta-AnalysisFull text (PMC)
Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis.
Chung Vincent C H, Ma Polly H X, Hui David S C et al. · PLoS One · 2013
PMID: 23967106Meta-AnalysisFull text (PMC)
Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
Jiang Fa-Ming, Liang Zong-An, Zheng Qiao-Ling et al. · Lung · 2013
PMID: 23306410Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Indacaterol (substance)
SNOMED CT
702801003
UMLS CUI
C1722260
RxNorm CUI
1114326

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
19
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.